Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A multimodal analgesic cocktail developed by Peking Union Medical College Hospital for periarticular infiltration during total knee arthroplasty in patients with osteoarthritis. The mixture contains ropivacaine (a local anesthetic), morphine (an opioid), flurbiprofen (an NSAID), and epinephrine (a vasoconstrictor). This combination is designed to provide localized, long-lasting pain relief by targeting multiple pain pathways: ropivacaine blocks sodium channels to inhibit nerve conduction, morphine activates mu-opioid receptors, flurbiprofen inhibits cyclooxygenase enzymes to reduce inflammation, and epinephrine prolongs the local effect by inducing vasoconstriction. It is administered directly into the surgical site (periarticular and intraarticular) to improve postoperative recovery and reduce the need for systemic opioids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + morphine + flurbiprofen + epinephrine.